CorMedix Inc
CRMD14.830USD
+0.480+3.34%
終値 08/29, 16:00（ET）15分遅れの株価
1.11B時価総額
64.41直近12ヶ月PER
詳細情報 CorMedix Inc 企業名
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
企業情報
企業コードCRMD
会社名CorMedix Inc
上場日Mar 25, 2010
最高経営責任者「CEO」Mr. Joseph Todisco
従業員数64
証券種類Ordinary Share
決算期末Mar 25
本社所在地300 Connell Drive
都市BERKELEY HEIGHTS
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号07922
電話番号19085179500
ウェブサイトhttps://cormedix.com/
企業コードCRMD
上場日Mar 25, 2010
最高経営責任者「CEO」Mr. Joseph Todisco
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
収益内訳
FY2025Q1
FY2024
データなし
地域別USD
会社名
収益
比率
United States
39.08M
0.00%
事業別
地域別
データなし
株主
更新時刻: Sun, Aug 31
更新時刻: Sun, Aug 31
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
6.42%
Abdalkader (Shaibatalhamd Aymen)
6.22%
The Vanguard Group, Inc.
5.77%
Marshall Wace LLP
3.46%
Citadel Advisors LLC
2.30%
他の
75.83%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
6.42%
Abdalkader (Shaibatalhamd Aymen)
6.22%
The Vanguard Group, Inc.
5.77%
Marshall Wace LLP
3.46%
Citadel Advisors LLC
2.30%
他の
75.83%
種類
株主統計
比率
Investment Advisor
22.34%
Investment Advisor/Hedge Fund
13.04%
Hedge Fund
8.73%
Individual Investor
7.30%
Research Firm
1.48%
Sovereign Wealth Fund
1.26%
Pension Fund
0.63%
Bank and Trust
0.28%
Venture Capital
0.06%
他の
44.87%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
280
26.40M
35.51%
-7.69M
2025Q1
281
29.73M
44.27%
-179.25K
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
4.31M
5.8%
+109.81K
+2.61%
Mar 31, 2025
The Vanguard Group, Inc.
3.63M
4.89%
+255.97K
+7.58%
Mar 31, 2025
Marshall Wace LLP
230.53K
0.31%
+230.53K
--
Mar 31, 2025
State Street Global Advisors (US)
1.54M
2.07%
+85.97K
+5.92%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.43M
1.93%
+40.10K
+2.88%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Wed, Aug 6
更新時刻: Wed, Aug 6
銘柄名
比率
Invesco Dorsey Wright Healthcare Momentum ETF
1.62%
SPDR S&P Pharmaceuticals ETF
1.31%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.81%
First Trust Active Factor Small Cap ETF
0.41%
Vanguard US Momentum Factor ETF
0.21%
iShares Micro-Cap ETF
0.18%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
詳細を見る
Invesco Dorsey Wright Healthcare Momentum ETF
比率1.62%
SPDR S&P Pharmaceuticals ETF
比率1.31%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率0.81%
First Trust Active Factor Small Cap ETF
比率0.41%
Vanguard US Momentum Factor ETF
比率0.21%
iShares Micro-Cap ETF
比率0.18%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.09%
ProShares Ultra Nasdaq Biotechnology
比率0.09%
iShares Biotechnology ETF
比率0.08%
Invesco Nasdaq Biotechnology ETF
比率0.08%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
